Loading news...
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Frederick Hudson sold 5,369 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Victory Capital Management Inc. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 25.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 559,835 shares of the specialty pharmaceutical company's stock after selling 191,708 shares during the quarter.
American Century Companies Inc. trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 44.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 509,368 shares of the specialty pharmaceutical company's stock after selling 406,786 shares during the period. American Century Companies
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the SEC, which can be
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago.
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively.
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial.
AdvisorShares Investments LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,525 shares of the specialty pharmaceutical company's stock, valued at approximately $742,000. A number of other institutional
Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset by pipeline and acquisitions. The Sage Therapeutics acquisition adds near-term revenue and pipeline depth, though pipeline maturity limits major new launches before 2027.
SG Americas Securities LLC decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 51.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,353 shares of the specialty pharmaceutical company's stock after selling 11,070 shares during the
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received an average recommendation of "Hold" from the seven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) VP Padmanabh Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares in
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the
Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter.